Morepen Labs elevates Sanjay Suri to MD, extends medtech spin-off timeline
- Sanjay Suri elevated from Whole-Time Director to Managing Director
- Timeline extended for hiving off Medical Devices business into subsidiary
- Final dividend of ₹0.20 per share declared for FY26
- Sushil Suri reappointed as Chairman and Managing Director
- Meeting held virtually with 92 members present
*this image is generated using AI for illustrative purposes only.
Morepen Laboratories Limited shareholders approved the elevation of Sanjay Suri from Whole-Time Director to Managing Director during the company's 41st Annual General Meeting held on September 26, 2026. The meeting also ratified the extension of the deadline for separating the Medical Devices business into a subsidiary.
The proceedings were conducted via Video Conferencing/Other Audio-Visual Means in compliance with Ministry of Corporate Affairs and SEBI regulations. Sushil Suri, Chairman and Managing Director, chaired the session except for specific agenda items handled by Independent Director Praveen Kumar Dutt. A quorum of 92 members was present through the virtual platform.
Key resolutions passed
The shareholders adopted several ordinary and special business items, including the audited financial statements for FY26 and the appointment of directors. The final dividend declaration and auditor remuneration ratifications were also approved.
| Item | Particulars | Resolution Type |
|---|---|---|
| 1 | Adoption of audited financial statements for FY26 | Ordinary |
| 2 | Declaration of final dividend of ₹0.20 per equity share | Ordinary |
| 3 | Reappointment of Sanjay Suri (retiring by rotation) | Ordinary |
| 4 | Ratification of cost auditor remuneration for FY27 | Ordinary |
| 5 | Elevation of Sanjay Suri to Managing Director | Special |
| 6 | Reappointment of Sushil Suri as Chairman & MD | Special |
| 7 | Extension of timeline for Medical Devices business hive-off | Special |
Leadership changes and strategic shifts
A significant governance update involved the change in designation for Sanjay Suri. Having retired by rotation and offered himself for reappointment, he was elevated from his previous role as Whole-Time Director to Managing Director via a special resolution. Simultaneously, Sushil Suri was reappointed as Chairman and Managing Director.
The most material strategic development concerned the Medical Devices Business. Shareholders approved the extension of the approved timeline for hiving off this segment into Morepen Medipath Limited (formerly Morepen Medtech Limited), a wholly owned subsidiary. This transaction is structured as a going concern on a slump sale basis and is classified as a material related party transaction.
Voting and procedural details
The company provided electronic voting facilities both remotely and during the meeting. Remote e-voting was open from September 23 to September 25, 2026. Mr. Praveen Dua of M/s P D and Associates served as the scrutinizer to ensure fair transparency in the voting process. The meeting concluded at 2:15 pm IST.
Historical Stock Returns for Morepen Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.24% | -0.15% | +26.42% | +229.36% | +136.92% | +111.56% |
How will the leadership transition to Sanjay Suri as Managing Director influence Morepen Laboratories' strategic priorities for FY27?
What specific operational or financial benefits does Morepen anticipate from the delayed hive-off of its Medical Devices business?
How might the extension of the Medical Devices subsidiary separation timeline impact the valuation of Morepen Medipath Limited?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
